

PHASEIN

PRESS RELEASE 2003-01-17

25 MSEK to new Swedish Med-Tech Company

Karolinska Investment Fund and SEB Företagsinvest today announced their decision to invest 25 MSEK in PHASEIN AB a Stockholm based Med-Tech Company.

PHASEIN develops a new technology that improves measurement and monitoring of patient vital signs within anaesthesia, recovery, transport and intensive care.

- We are very pleased to have attracted experienced investors who are very competent within the field of medical technology, comments Robert Zyzanski, CEO of PHASEIN.

- PHASEIN's unique technology will lead to significant clinical and economical improvements in the area of health care, which was very important for our investment decision, comments Stefan Winberg, Karolinska Investment Fund.

- A key factor for our decision to invest in PHASEIN was the founders experience as entrepreneurs having earlier built a successful company in this particular field, comments Ola Romney, SEB Företagsinvest.

PHASEIN will become one of a few companies within its field that is completely independent of the technologies of other companies. This provides PHASEIN with the necessary base for growth and for becoming a leading supplier in the area of patient monitoring.

The world market for PHASEIN's niche within patient monitoring is estimated to be worth around USD 500 million in 2002. Growth is expected to be around 5-7%.

- We want to combine PHASEIN's technological edge with our international contact network to give the company a prominent position on the world market, Robert Zyzanski concludes.

PHASEIN develops and markets ultra compact multi-parameter probes for the monitoring of patient vital signs within anaesthesia, intensive care and emergency care. The target group for the Company's products consists of international companies working within the field of anaesthesia, intensive care and emergency care.

Karolinska Investment Fund (KIF) is a venture capital fund set up in 1999 by the Karolinska Institute and the insurance company Alecta. The Fund invests in research and development projects, primarily in the areas of pharmaceuticals, biotechnology and medical technology. For further information about Karolinska Investment Fund, see www.karolinskafund.com

SEB Företagsinvest is the venture capital arm of Skandinaviska Enskilda Banken (SEB). The business concept is to invest venture capital and to provide competence and an extensive network of contacts for growth companies in Technology and Healthcare. Since it was started in 1995, SEB Företagsinvest has invested in 47 companies, of which 17 have been exited. For more information, see www.foretagsinvest.seb.se

Further statement will be issued as and when appropriate

For further information:

Robert Zyzanski, CEO, PHASEIN

Stefan Winberg, Investment Manager, KIF

Ola Romney, Senior Investment Manager, SEB Företagsinvest

Telephone: +46 8 544 98 166

Telephone: +46 8 5088 44 57

Telephone: +46 8 763 79 13